Senti Biosciences, Inc. (SNTI)
NASDAQ: SNTI · Real-Time Price · USD
3.210
-0.034 (-1.05%)
At close: Apr 2, 2025, 4:00 PM
3.130
-0.080 (-2.49%)
After-hours: Apr 2, 2025, 5:07 PM EDT
Senti Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
34
Market Cap
83.47M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SNTI News
- 13 days ago - Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights - GlobeNewsWire
- 20 days ago - Senti Bio Appoints Feng Hsiung to Board of Directors - GlobeNewsWire
- 5 weeks ago - Senti Bio Strengthens Leadership Team with Strategic Hires - GlobeNewsWire
- 3 months ago - Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics - GlobeNewsWire
- 4 months ago - Senti Biosciences Announces New Employment Inducement Grants - GlobeNewsWire
- 4 months ago - Why Is Senti Biosciences Stock Surging Over 400% On Monday? - Benzinga
- 4 months ago - Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing - GlobeNewsWire
- 4 months ago - Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML - GlobeNewsWire